” A comparative double-blind placebo-controlled study between alizapride and ondansetron for the prevention of postoperative nausea and vomiting.”

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-004789-20-BE

Enrollment

520

Registered

2008-07-29

Start date

2008-09-05

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of post-operative nausea and vomiting.

Interventions

Trade Name: Litican Product Name: Litican Product Code: A03FA05 Pharmaceutical Form: Injection* CAS Number: 59338-87-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration num

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - ASA 1 and 2 - planned laparoscopic gynaecological surgery - cooperative patients - signed informed consent - female patients over 18 years old Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - ASA 3 and 4 - non-cooperative patients - allergy to alizapride or ondansetron - refusal of the patient - Parkinson's disease - pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: Are Alizapride and ondansetron equally effectieve for the prevention of post-operative nausea and vomiting.;Secondary Objective: ;Primary end point(s): The primary efficacy end point of this study is the composite total post-operative Nausea and Vomiting after the treatment period.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026